血清素-去甲肾上腺素-多巴胺再摄取抑制剂(英语:serotonin–norepinephrine–dopamine reuptake inhibitorSNDRI),也称作三重再摄取抑制剂TRI),是多种单胺神经递质再摄取抑制剂,原理为通过抑制5-羟色胺转运体去甲肾上腺素转运体多巴胺转运体体来分别抑制5-羟色胺去甲肾上腺素多巴胺的再摄取。这个作用会增加这些神经递质在突触间隙的浓度。

SNDRI作为一系列疾病的药物候选而被开发,如抗忧郁剂[1][2][3][4][5] 和治疗肥胖古柯碱成瘾注意力缺陷/过动症(ADHD)及慢性疼痛的药物。SNDRI作为选择性血清素再吸收抑制剂(SSRIs)及血清素-去甲肾上腺素再吸收抑制剂(SNRIs)的延伸,增加了多巴胺再吸收抑制作用,这被认为具有增加疗效的可能,但副作用药物滥用的可能也随之增加。

引用

编辑
  1. ^ Musk, P. Magic shotgun methods for developing drugs for CNS disorders. Discovery medicine. 2004, 4 (23): 299–302. PMID 20704963. 
  2. ^ Millan, MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2009, 6 (1): 53–77. PMID 19110199. doi:10.1016/j.nurt.2008.10.039. 
  3. ^ Chen, Z; Skolnick, P. Triple uptake inhibitors: Therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs. 2007, 16 (9): 1365–77. PMID 17714023. doi:10.1517/13543784.16.9.1365. 
  4. ^ Perona, MT; Waters, S; Hall, FS; Sora, I; Lesch, KP; Murphy, DL; Caron, M; Uhl, GR. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: Prominent effects of dopamine transporter deletions. Behavioural Pharmacology. 2008, 19 (5–6): 566–74. PMC 2644662 . PMID 18690111. doi:10.1097/FBP.0b013e32830cd80f. 
  5. ^ Chen, Z; Yang, J; Tobak, A. Designing new treatments for depression and anxiety. IDrugs : the investigational drugs journal. 2008, 11 (3): 189–97. PMID 18311656.